122 related articles for article (PubMed ID: 18277013)
1. [Pre-clinical and clinical profiles of celecoxib, a new specific cyclooxygenase-2 inhibitor].
Kimoto A; Hanaoka A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2008 Feb; 131(2):127-36. PubMed ID: 18277013
[No Abstract] [Full Text] [Related]
2. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function.
Hu F; Wang X; Pace TW; Wu H; Miller AH
Mol Psychiatry; 2005 May; 10(5):426-8. PubMed ID: 15700047
[No Abstract] [Full Text] [Related]
3. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Tuynman JB; Buskens CJ; Kemper K; ten Kate FJ; Offerhaus GJ; Richel DJ; van Lanschot JJ
Ann Surg; 2005 Dec; 242(6):840-9, discussion 849-50. PubMed ID: 16327494
[TBL] [Abstract][Full Text] [Related]
4. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
Awara WM; El-Sisi AE; El-Sayad ME; Goda AE
Pharmacol Res; 2004 Nov; 50(5):487-98. PubMed ID: 15458769
[TBL] [Abstract][Full Text] [Related]
5. Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation.
Rodriguez-Burford C; Tu JH; Mercurio M; Carey D; Han R; Gordon G; Niwas S; Bell W; Elmets CA; Grizzle W; Pentland AP
J Invest Dermatol; 2005 Dec; 125(6):1317-20. PubMed ID: 16354205
[No Abstract] [Full Text] [Related]
6. Correction of endothelial dysfunction in patients with arterial hypertension.
Soloviev MA; Kulakova NV; Semiglazova TA; Borodulina EV; Udut VV
Bull Exp Biol Med; 2011 Jun; 151(2):183-5. PubMed ID: 22238745
[TBL] [Abstract][Full Text] [Related]
7. The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo.
Kasukawa Y; Miyakoshi N; Srivastava AK; Nozaka K; Maekawa S; Baylink DJ; Mohan S; Itoi E
Tohoku J Exp Med; 2007 Mar; 211(3):275-83. PubMed ID: 17347553
[TBL] [Abstract][Full Text] [Related]
8. Preventing chronic pain after surgery: who, how, and when?
Eisenach JC
Reg Anesth Pain Med; 2006; 31(1):1-3. PubMed ID: 16418016
[No Abstract] [Full Text] [Related]
9. Celecoxib: a novel treatment for lung cancer.
Abou-Issa H; Alshafie G
Expert Rev Anticancer Ther; 2004 Oct; 4(5):725-34. PubMed ID: 15485309
[TBL] [Abstract][Full Text] [Related]
10. Prominent celecoxib researcher admits fabricating data in 21 articles.
Lenzer J
BMJ; 2009 Mar; 338():b966. PubMed ID: 19273517
[No Abstract] [Full Text] [Related]
11. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
Bundscherer A; Hafner C; Maisch T; Becker B; Landthaler M; Vogt T
Oncol Rep; 2008 Feb; 19(2):547-53. PubMed ID: 18202806
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral effect of celecoxib in hepatocellular carcinoma.
Malka D; Pacault V; De Baere T; Ducreux M; Boige V
J Clin Oncol; 2005 Jul; 23(21):4805-6. PubMed ID: 16034068
[No Abstract] [Full Text] [Related]
13. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18627117
[No Abstract] [Full Text] [Related]
15. PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Sonpavde G; Hayes TG
Mayo Clin Proc; 2005 Aug; 80(8):1100-1. PubMed ID: 16092593
[No Abstract] [Full Text] [Related]
16. COX-2 inhibitors still eyed for cancer prevention.
Thompson CA
Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
[No Abstract] [Full Text] [Related]
17. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
[TBL] [Abstract][Full Text] [Related]
18. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Noguchi M; Kimoto A; Kobayashi S; Yoshino T; Miyata K; Sasamata M
Eur J Pharmacol; 2005 Apr; 513(3):229-35. PubMed ID: 15862805
[TBL] [Abstract][Full Text] [Related]
19. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
Cotter J; Wooltorton E
CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921
[No Abstract] [Full Text] [Related]
20. Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.
Chu LM; Robich MP; Bianchi C; Feng J; Liu Y; Xu SH; Burgess T; Sellke FW
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(2):H479-88. PubMed ID: 22037194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
